AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 12- Open
- $0.47
- 52-wk high
- $24.30
- High
- $0.47
- 52-wk low
- $0.33
- Low
- $0.38
- Prev close
- $0.70
- Mkt cap
- $1.5M
- Volume
- 118.47M
- Beta
- 1.35
- P/S
- 0.0x
- P/B
- 0.1x
- Profit margin
- -16.5%
- Op margin
- -17.4%
- ROE
- -21.9%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about SBFM filings
Are insiders buying or selling Sunshine Biopharma Inc (SBFM) stock?
Neither. Sunshine Biopharma Inc (SBFM) insiders filed no open-market purchases or sales in the 90 days to Oct 12, 2026, according to SEC Form 4 filings.
Which members of Congress have traded SBFM recently?
None. No member of Congress disclosed a SBFM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this SBFM smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
1 fund holds a position.
How top traders are positioned
No tracked top-trader positions in SBFM right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No reported figure for the latest quarter.
Company release linked above, where available
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | Unavailable | - | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 3, 2026 | -$2.50 / -$1.60Alpha Vantage | -56.25% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 25, 2026 | -$0.46 / -$0.12Alpha Vantage | -$0.34 miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 13, 2025 | -$1.90 / -$1.30Alpha Vantage | -46.15% miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 12, 2025 | -$3.90 / -$1.10Alpha Vantage | -$2.80 miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 15, 2025 | -$0.44 / $0.07Alpha Vantage | -$0.51 miss | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 31, 2025 | Unavailable | - | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 5, 2024 | -$9.40 / -$5350.00Alpha Vantage | +99.82% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 12, 2026, in 31 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -16.5%
- Market cap
- $1M
Valuation
- P/S0.04
- P/B0.13
Quality
- Operating margin-17.4%
- ROE-21.9%
- ROA-9.9%
Growth
- Beta1.35
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace